Candel Therapeutics (NASDAQ:CADL) Stock Price Target Cut by Stifel Nicolaus

Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its target price lowered by Stifel Nicolaus from $22.00 to $19.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus‘s price target would indicate a potential upside of 126.46% from the company’s current price.

A number of other research firms have also weighed in on CADL. Jefferies Financial Group started coverage on shares of Candel Therapeutics in a research report on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price objective on the stock. Zacks Research downgraded shares of Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Bank of America upgraded Candel Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $12.00 to $18.00 in a research report on Monday, September 21st. Wall Street Zen downgraded Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Candel Therapeutics in a research note on Friday, October 2nd. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Get Our Latest Stock Analysis on CADL

Candel Therapeutics Trading Down 9.0%

CADL stock opened at $8.39 on Friday. Candel Therapeutics has a twelve month low of $4.35 and a twelve month high of $14.00. The stock has a market capitalization of $642.00 million, a price-to-earnings ratio of -5.95 and a beta of -0.27. The company has a quick ratio of 16.09, a current ratio of 16.09 and a debt-to-equity ratio of 0.38. The firm’s fifty day simple moving average is $9.89 and its two-hundred day simple moving average is $8.39.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. As a group, analysts anticipate that Candel Therapeutics will post -1.29 earnings per share for the current year.

Insider Buying and Selling

In related news, CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.00, for a total transaction of $84,000.00. Following the completion of the sale, the chief technology officer owned 76,865 shares in the company, valued at $922,380. This trade represents a 8.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 14.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Candel Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Candel Therapeutics during the second quarter worth approximately $51,181,000. Bank of America Corp DE bought a new stake in shares of Candel Therapeutics during the second quarter valued at approximately $2,873,000. Wellington Management Group LLP bought a new stake in shares of Candel Therapeutics during the second quarter valued at approximately $2,119,000. Bank of New York Mellon Corp purchased a new stake in shares of Candel Therapeutics in the second quarter valued at approximately $1,975,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of Candel Therapeutics in the first quarter valued at approximately $845,000. 13.93% of the stock is currently owned by institutional investors.

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Further Reading

Analyst Recommendations for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.